Skip To Main Content
Stephan Bohl on Muck Rack

Stephan Bohl

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Stephan Bohl’s profile

Articles by Stephan Bohl

Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy

|
By Michael Korenkov, Vincent Fregona, Maximilian Sprechert, Alexandra Polici, Clarissa K. Heck, Simon J. Haas, Jan Krönke, Ulrich Keller, Stephan Bohl, Frederik Herzberg, Feiteng Lu, Carin Didoss, Nina Heisterkamp
| Nature Verified
Abstract Bispecific T cell engagers (TCE) targeting BCMA or GPRC5D have improved outcomes in relapsed/refractory multiple myeloma (MM), yet up to 40% of patients are primarily refractory, and predictive biomarkers are scarce. To address this unmet clinical need, we developed an image-based, high-content ex vivo assay using patient-derived bone marrow mononuclear cells exposed to teclistamab or talquetamab.
Open in Who Shared Issue with article?

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

|
By Marc S. Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Roland Fenk, Katja Weisel, Lilli Podola, Uta Bertsch, Alexander Brobeil, Julia Mersi, Stefanie Huhn, Ryan Arlinghaus, Michael Hundemer, Stephan Bohl, Elias K. Mai, Natalie Schub, Johannes M. Waldschmidt, Florian Bassermann, Carsten Müller-Tidow, Christoph J. Heuck, Caline Sakabedoyan, Josephine Khan, Elena Ershova, Bas D. Koster, Monika Engelhardt, Mathias Hänel, Hans Salwender, Raphael Teipel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04471-x, published online 25 June 2026.
Open in Who Shared Issue with article?

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

|
By Marc S. Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Roland Fenk, Katja Weisel, Uta Bertsch, Alexander Brobeil, Stefanie Huhn, Michael Hundemer, Stephan Bohl, Elias K. Mai, Natalie Schub, Johannes M. Waldschmidt, Florian Bassermann, Carsten Müller-Tidow, Christoph J. Heuck, Elena Ershova, Bas D. Koster, Monika Engelhardt, Mathias Hänel, Hans Salwender, Raphael Teipel, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche, Lilli Podola, Julia Mersi, Ryan Arlinghaus, Caline Sakabedoyan, Josephine Khan
| Nature Verified
Abstract Advancements in frontline therapies have substantially improved outcomes in newly diagnosed multiple myeloma (NDMM); however, many patients will not achieve deep responses and will relapse. Teclistamab, a BCMA×CD3 bispecific antibody, in combination with daratumumab, has demonstrated strong efficacy in relapsed/refractory multiple myeloma versus standard of care as early as first relapse.
Open in Who Shared Issue with article?

Transferability of a US claims-based machine learning model for ATTRwt-CM identification: a retrospective evaluation in a German setting

|
By Miriam R. Hübner, Isabel Mattig, Paul J. Wetzel, Helena F. Pernice, Gina Barzen, Nicolas Wieder, Jakub P. Piwowarski, Daniel R. Messroghli, Sebastian Spethmann, Richard Röttger, Josef Schepers, Katrin Hahn, Harisa Muratovic-Colic, Jan-Filip Rehburg, Katrin Wrede-Wihl, Stephan Bohl, Vera von Landenberg-Roberg
| Nature Verified
Abstract Cardiac amyloidosis (CA), a fatal and progressive cardiomyopathy is characterized by amyloid deposition within the myocardium. The main forms of CA include transthyretin amyloidosis (ATTR-CM; distinguished into a hereditary and wildtype form [ATTRv and ATTRwt]) and light-chain amyloidosis (AL). Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is increasingly recognized among heart failure (HF) patients, despite its underestimated prevalence as a rare disease.
Open in Who Shared Issue with article?
Show More